AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge

AbbVie Inc.

2025-FY EPS reported $2.36 vs consensus $2.71 ▼ miss (-12.8%)

Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.
Full-year 2025 adjusted EPS guidance lowered to $9.90-$9.94 from $10.61-$10.65.
Pre-tax acquired IPR&D and milestones expense of $1,265M (unfavorable $0.71 to GAAP and adjusted EPS).
Q4 2025 results not finalized; expense relates to collaborations and licensing deals.
AbbVie does not forecast IPR&D/milestones expense due to uncertainty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.